ISSN:
1437-160X
Keywords:
Key words Rheumatoid arthritis
;
Granulocyte and monocyte apheresis
;
Iliac bone marrow
;
CD15+CD16
;
cells
;
Joint counts
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract To investigate if granulocyte and monocyte apheresis mitigates the symptoms of rheumatoid arthritis (RA), and influences production of panmyelocytes (CD15+ CD16– cells) at the bone marrow level, 27 RA patients who had elevated granulocyte counts were recruited. The granulocyte and monocyte apheresis column (G-1 column) is an extracorporeal type device packed with 220 g cellulose acetate beads to which granulocytes and monocytes specifically adhere. Patients received apheresis of 1 hr duration twice per week, 8 times over a period of 4 weeks. To prepare CD15+CD16– cells, iliac bone marrow aspirate was obtained at baseline and at 2 weeks after completion of the apheresis course. Ex-vivo proliferation of bone marrow low density cells and production of IgM-RF were also investigated. Following granulocyte and monocyte apheresis, there was a suppressed tendency in the number of CD15+CD16– cells in patients with high bone marrow CD15+CD16– cell counts at baseline. Clinical assessments 2 weeks after the completion of apheresis therapy showed improvements in swollen joint count (P〈0.001), tender joint count (P〈0.001) and duration of morning stiffness (P〈0.005). The results suggest that granulocytes and monocytes/macrophages have a pathological role in RA and apheresis treatment to reduce or suppress these cells should benefit patients with RA.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/s002960050068
Permalink
